title: [Stroke prevention in atrial fibrillation : old and new anticoagulants].
abstract: Atrial fibrillation is the most common form of cardiac arrhythmia with an age-dependent increase in prevalence. It is common clinical practice to treat patients with atrial fibrillation and who have a high risk for thromboembolic stroke with vitamin K antagonists. However, due to the many problems with vitamin K antagonist therapy many high risk patients are either not treated at all or receive insufficient anticoagulation treatment. The new oral anticoagulants, e.g. dabigatran as a direct thrombin antagonist or rivaroxaban and apixaban as factor Xa antagonists were tested in large scale clinical trials with respect to the efficacy in stroke prevention in atrial fibrillation patients. The therapeutic superiority over warfarin could be impressively proven either with respect to the efficacy in stroke prevention and/or to the safety of therapy with a significant decrease in cerebral bleeding complications.
authors: Klinik f. Kardiologie, Angiologie u. Intensivmedizin, Vivantes Klinikum Neukölln, Rudower Str. 48, 12351, Berlin, Deutschland. harald.darius@vivantes.de
authors: H
authors: H
authors: Darius
authors: S
authors: S
authors: Sommer
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D001562:Benzimidazoles / Q000008:administration & dosage*; D000069604:Dabigatran; D065427:Factor Xa Inhibitors; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage*; D011720:Pyrazoles / Q000008:administration & dosage*; D011728:Pyridones / Q000008:administration & dosage*; D000069552:Rivaroxaban; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D013876:Thiophenes / Q000008:administration & dosage*; D014812:Vitamin K / Q000037:antagonists & inhibitors*; D015091:beta-Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D065427:Factor Xa Inhibitors; D009025:Morpholines; D011720:Pyrazoles; D011728:Pyridones; D013876:Thiophenes; D015091:beta-Alanine; D014812:Vitamin K; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran
references: Thromb Haemost. 2010 Sep;104(3):633-41
references: 20694273
references: Circulation. 2011 May 31;123(21):2363-72
references: 21576658
references: Circulation. 2012 Sep 4;126(10):1185-93
references: 22869839
references: Stroke. 2009 Jan;40(1):235-40
references: 18757287
references: N Engl J Med. 2011 Mar 3;364(9):806-17
references: 21309657
references: Lancet. 2006 Jun 10;367(9526):1903-12
references: 16765759
references: Am Heart J. 2009 Nov;158(5):713-8
references: 19853687
references: N Engl J Med. 2011 Sep 15;365(11):981-92
references: 21870978
references: Circulation. 2012 Feb 7;125(5):669-76
references: 22215856
references: Can J Cardiol. 2012 Mar-Apr;28(2):125-36
references: 22433576
references: Europace. 2012 Oct;14(10):1385-413
references: 22923145
references: Europace. 2010 Oct;12(10):1360-420
references: 20876603
references: N Engl J Med. 2009 May 14;360(20):2066-78
references: 19336502
references: Circulation. 2011 Jan 4;123(1):104-23
references: 21173346
references: N Engl J Med. 2011 Sep 8;365(10):883-91
references: 21830957
references: Chest. 2012 Feb;141(2 Suppl):7S-47S
references: 22315257
references: N Engl J Med. 2009 Sep 17;361(12):1139-51
references: 19717844
references: Thromb Haemost. 2011 Nov;106(5):968-77
references: 21901239
references: J Thromb Haemost. 2008 Sep;6(9):1500-6
references: 18573187
references: Expert Rev Cardiovasc Ther. 2012 Aug;10(8):965-72
references: 23030284